PARIS – September 9, 2021 – The Phase 3 PEGASUS trial evaluating rilzabrutinib to treat pemphigus, a rare autoimmune skin condition, did not meet its primary or key secondary endpoints.

A new study published in the journal of JID Innovations revealed that pemphigus is not significantly associated with an ...

August 8, 2007 — A single cycle of rituximab was an effective treatment for pemphigus, according to the results of a small, prospective, open study reported in the August 9 issue of the New England ...

Scientists at Scripps Research have reported success in initial tests of a new, nanotech-based strategy against autoimmune diseases. The National Institutes of Health has begun a clinical trial to ...

Please provide your email address to receive an email when new articles are posted on . A trial of adjuvant immunoadsorption for pemphigus diseases was ended early due to adverse events. The time to ...